ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Engineering Adenine Deaminase TadA for Precise and PAM-Flexible Point Mutagenesis and Gradient-Tuning Endogenous Protein Design.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Systematic Profiling of ssODN Determinants Establishes Optimized LbCas12a-Mediated HDR for Precise Genome Editing inJournal of fungi (Basel, Switzerland) · 2026Article
- Optimized TadA-derived base editors efficiently manipulate mRNA splicing by A-to-G and C-to-K editing in potato.Journal of integrative plant biology · 2026Article
- DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects.Molecular biomedicine · 2026Review
- Transactivation of AGPL2 by Opaque2 is responsible for starch accumulation and kernel hardness in sweet corn.Journal of experimental botany · 2026Article
- Sustainable Production of Ginsenosides: Advances in Biosynthesis and Metabolic Engineering.Plants (Basel, Switzerland) · 2025Review
- Engineering Adenine Deaminase TadA for Precise and PAM-Flexible Point Mutagenesis and Gradient-Tuning Endogenous Protein Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Base editing enables precise nucleotide substitutions within a relatively broad editing window (5-6 nucleotides). However, considerable bystander editing significantly compromise its accuracy. Point mutagenesis, a powerful approach for gradient-tuning protein function, facilitates the generation of diverse plant phenotypes to meet the demands of complex environments and consumer preferences. Here, a series of plant base editors is engineered by fusing three optimized TadA8e variants, TadA9, TadA-LM, and TadA-dual, with a PAM-flexible SpRY nickase (SpRYn, with 5'-NNN PAM recognition). These editors enable A-to-G, C-to-T, and dual-base (simultaneous A-to-G and C-to-T) conversions within a highly condensed active window (1-3 nucleotides). Performance evaluations reveal that the TadDBE (TadA Dual-Base Editor) achieves the most robust outcomes, delivering dual-base editing efficiencies ranging from 2.3% to 61.4%, while maintaining minimal off-target activity. Utilizing TadDBE, targeted point mutagenesis is performed on OsBadh2, a gene encoding betaine aldehyde dehydrogenase that plays a critical role in the biosynthesis of 2-acetyl-1-pyrroline (2-AP), a key aromatic compound. This approach yields rice lines exhibiting gradient-tuned aromatic profiles and optimized levels of 2-AP and γ-aminobutyric acid (GABA). These evolved TadA-derived editors provide a precise, PAM-flexible platform for base editing and represent a versatile strategy for generating genome-edited plants with gradient-tuned agronomic traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.